Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Growing Hematology Pipeline Matures With New Hemophilia, Sickle Cell Data

Multiple Modalities Advance Across Non-Malignant Diseases

Executive Summary

The big pharma is building on its hematology legacy beyond coagulation factors with marstacimab and gene therapies for hemophilia, plus oral and injectable medicines for sickle cell disease.

You may also be interested in...



Sanofi’s Altuviiio Set To Reenergize Factor VIII Space

The once-weekly Factor VIII replacement therapy for hemophilia A, newly approved by the US FDA, appears well positioned to compete with Roche’s blockbuster Hemlibra.

Pfizer’s Gene Therapy Asset Chases UniQure/CSL’s Hemgenix After Pivotal Hemophilia B Success

Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.

Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise

Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel